Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen TEAs

This article was originally published in The Tan Sheet

Executive Summary

FDA requests safety and efficacy data on three sunscreens based on its determination that time and extent applications indicate the ingredients are "eligible for consideration" for inclusion in OTC monograph, according to 1July 11 Federal Register notice. Data sought on amiloxate (isoamyl p-methoxycinnamate), enzacamene (methyl benzylidene camphor) and octyl triazone by Oct. 9. TEAs for ingredients were filed by Haarmann & Reimer, Merck KgaA and BASF AG, respectively. Agency will make a final decision on ingredients' status following review of submitted information...

You may also be interested in...



Octyl triazone

BASF asks for 90-day extension to respond to FDA's request for data on octyl triazone sunscreen; the previous deadline was Oct. 9. Firm maintains more time is needed to compile recent effectiveness data. Beiersdorf submitted a separate letter Oct. 7 in support of BASF's time and extent application, noting the German firm has used the ingredient in its own sun care products outside the U.S. for more than five years without "unusual adverse event experience." FDA requested safety data on octyl triazone and two other sunscreen ingredients in a July 11 Federal Register notice (1"The Tan Sheet" July 14, 2003, In Brief)...

Octyl Triazone Sales Of 400 Mil. Sunscreen Units Abroad Cited By FDA

Based on bulk material sales, nearly 400 mil. sunscreen dosage units containing octyl triazone have been sold in 35 countries, FDA notes in an evaluation of BASF's time and extent application for including the ingredient in the OTC sunscreen monograph

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

PS095696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel